Oropharynx Cancer Clinical Trial
Official title:
The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors: A Randomized Clinical Trial
NCT number | NCT05798780 |
Other study ID # | MCC-22330 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 6, 2023 |
Est. completion date | January 2025 |
The purpose of the study is to design a physical activity and dietary intervention for head and neck cancer patients.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | January 2025 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - >18 years old - Newly diagnosed tumors of the oral cavity, oropharynx, hypopharynx, or larynx - No documented or observable psychiatric or neurological disorders that would interfere with study participation (e.g., dementia, psychosis) - Able to speak and read English - Able to consume food orally - Willing to consume an alternative Mediterranean diet - Scheduled to receive treatment with radiation or chemoradiation - Screened via the Physical Activity Readiness Questionnaire (PAR-Q+) with medical clearance of treating physicians, as necessary - Able to provide informed consent Exclusion Criteria: - Women who are pregnant - Head and Neck Cancer not the primary diagnosis - Patients scheduled to receive surgery - Patients on enteral or parental nutrition |
Country | Name | City | State |
---|---|---|---|
United States | Moffitt Cancer Center | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
H. Lee Moffitt Cancer Center and Research Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Recruited - Feasibility | The study will be deemed feasible if = 60% of eligible participants are enrolled | 12 Months | |
Primary | Number of Participants who Complete Questionnaire - Retention - Feasibility | The study will be deemed feasible if = 70% of participants complete post intervention questionnaire. | 12 weeks | |
Primary | Participant Satisfaction of Timeline - Feasibility | The study will be deemed feasible if = 70% of participants like the timing of the intervention using a likert scale (scale range Strongly agree to Strongly disagree) | 12 weeks | |
Primary | Participant Average Attendance - Assessment Completion - Adherence | Participant assessment completion will be deemed successful if participant average attendance is =10 weeks of sessions (out of 12) | 12 weeks | |
Primary | Number of Participants who Complete Task/Goals - Adherence | Study adherence will be deemed successful if =70% of participants report weekly tasks/goals adherence (e.g., gym and diet) | 12 weeks | |
Primary | Participant Satisfaction Assessed with 5 Point Scale - Acceptability | Participants satisfaction will be measured using a 5 point scale (1 is the lowest, 5 is the highest) exit survey administered at the post-intervention follow-up. | 12 weeks | |
Primary | Participant Intent to Continue Assessed with 5 Point Scale - Acceptability | Participants intent to continue will be measured using a 5 point scale (1 is the lowest, 5 is the highest) exit survey administered at the post-intervention follow-up. | 12 weeks | |
Primary | Participant Knowledge Gained Assessed with 5 Point Scale - Acceptability | Participants knowledge gained will be measured using a 5 point scale (1 is the lowest, 5 is the highest) exit survey administered at the post-intervention follow-up. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04444869 -
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT00158678 -
IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
|
Phase 3 | |
Completed |
NCT04567082 -
Proteome- and Methylation Profiles in Oropharyngeal Cancer
|
||
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Withdrawn |
NCT04001413 -
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
|
Phase 2 | |
Completed |
NCT03435471 -
Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer
|
N/A | |
Completed |
NCT05055206 -
Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers
|
N/A | |
Recruiting |
NCT04359199 -
QUantitative Assessment of Swallowing After Radiation (QUASAR)
|
||
Recruiting |
NCT05793151 -
Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy
|
N/A | |
Active, not recruiting |
NCT02908477 -
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
|
Phase 3 | |
Active, not recruiting |
NCT00232960 -
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
|
N/A | |
Completed |
NCT05698667 -
Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer
|
N/A | |
Recruiting |
NCT05757817 -
Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae
|
N/A | |
Active, not recruiting |
NCT02586207 -
Pembrolizumab in Combination With CRT for LA-SCCHN
|
Phase 1 | |
Completed |
NCT01108042 -
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03342378 -
PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
|
||
Active, not recruiting |
NCT03416153 -
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
|
Phase 2 | |
Terminated |
NCT01066741 -
Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer
|
Phase 3 | |
Completed |
NCT03418792 -
Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx
|
N/A | |
Recruiting |
NCT06088381 -
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
|
Phase 2 |